Asset Details
Do you wish to reserve the book?
Evinacumab for Homozygous Familial Hypercholesterolemia
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Evinacumab for Homozygous Familial Hypercholesterolemia
Do you wish to request the book?
Evinacumab for Homozygous Familial Hypercholesterolemia
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Evinacumab for Homozygous Familial Hypercholesterolemia
2020
Overview
Among 65 patients with homozygous familial hypercholesterolemia, the use of evinacumab, a monoclonal antibody against ANGPTL3, resulted in a reduction from baseline in the LDL cholesterol level, as compared with a small increase with placebo, for a between-group difference of 49.0 percentage points at 24 weeks.
Publisher
Massachusetts Medical Society
Subject
/ Adult
/ Aged
/ Angiopoietin-like Proteins - antagonists & inhibitors
/ Antibodies, Monoclonal - adverse effects
/ Antibodies, Monoclonal - blood
/ Antibodies, Monoclonal - therapeutic use
/ Anticholesteremic Agents - adverse effects
/ Anticholesteremic Agents - blood
/ Anticholesteremic Agents - therapeutic use
/ Child
/ Female
/ Humans
/ Hyperlipoproteinemia Type II - blood
/ Hyperlipoproteinemia Type II - drug therapy
/ Hyperlipoproteinemia Type II - genetics
/ Lipids
/ Male
/ Mutation
/ Patients
